|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's range||6.83 - 7.25|
|52-week range||4.06 - 12.09|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.00|
VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA, November 30, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology c
We can readily understand why investors are attracted to unprofitable companies. For example, although...
A look at the shareholders of BriaCell Therapeutics Corp. ( TSE:BCT ) can tell us which group is most powerful...